medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2017, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2017; 33 (2)

Evaluation of CD45 antigen expression in acute lymphoblastic leukemia

Marsán SV, Macías AC, Díaz DG, Morales GY, Lam DRM, Machín GS, González OA, Fernández NR, Cedré HT, Valdés SC

Language: Spanish
References: 23
Page: 1-11
PDF size: 156.55 Kb.


ABSTRACT

Introduction: Acute lymphoblastic leukemia (ALL) is the most frequent neoplasia in infancy. Determination of CD45 antigen discriminates between blasts and reactive cells in the bone marrow (MO).
Objective: To evaluate the expression of the CD45 antigen on the blasts of patients with ALL, according to the different immunological subtypes, their possible relation with the biological and clinical characteristics of the disease and the response to antileukemic treatment.
Methods: 150 patients with ALL were studied from various onco-hematological services of the country, between January 2008 and May 2015. The cellular immunophenotyping of the MO was performed by flow cytometry.
Results: The CD45 antigen showed a great heterogeneity of expression on the lymphoblasts. Of the total number of patients studied, 19.3% did not express the CD45 antigen on the blasts, 36.7% presented moderate expression and 44% showed a high expression density of it.A significant difference was found when comparing the leukemic phenotype with the expression of the CD45 antigen on the blasts (p = 0.000). No patient had mediastinal lymphadenopathy, with significant differences (p = 0.000), according to the phenotype and CD45 expression. Patients with T-ALL whose blasts did not express CD45 had a poor response to anti-leukemic treatment on days 8 and 15 in peripheral blood and MO, respectively.
Conclusion: CD45 expression on blasts could be considered as an additional prognostic factor for stratification in different risk groups of ALL in children.


REFERENCES

  1. Lassaletta A. Leucemias. Leucemia linfoblástica aguda. Pediatr Integral 2012;16:453-62.

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2012;61(2):69-90.

  3. Khoury MJ, Lam TK , Loannidis JP , Hartge P , Spitz MR , Buring JE , et al. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev 2013;22(4):508-16.

  4. Gerardo CJ, Rodríguez C, Sastre D, Heller V, Fernández E. Utilización estratégica de CD45 en la identificación de células blásticas por citometría de flujo. Acta Bioquím Clín Latinoam 2006;40(2):173-80.

  5. Ortolani C. CD45 Antigen. In: Ortolani C, editor. Flow Cytometry of Hematological Malignancies. UK: Wiley-Black Well;2011. p. 70-4.

  6. Shivtiel S , Lapid K , Kalchenko V , Avigdor A , Goichberg P , Kalinkovich A , et al. CD45 regulates homing and engraftment of immature normal and leukemic human cells in transplanted immunodeficient mice. Exp Hematol. 2011;39(12):1161-70.

  7. Saunders AE, Johnson P. Modulation of immune cell signaling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal. 2010;22(3):339-48.

  8. Saunder AE, Shim YA, Johnson P. Innate Immune Cell CD45 Regulates Lymphopenia-Induced T Cells Proliferation. J Immunol. 2014;193(6):2831-42.

  9. Van Dongen JJ, Lhermitte L, Botteher S. Euro Flow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leucocytes. Leukemia. 2012;26(9):1908-75.

  10. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen N, et al. Euro Flow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.

  11. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. Leukemia. 1995;9(10):1783-6.

  12. Kier KL. Biostatistical applications in epidemiology. Pharmacother. 2011;31(1):9-22.

  13. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-4.

  14. Haycocks NG, Lawrence L, Cain JW, Zhao XF. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia. Cytometry B Clin Cytom. 2011;80(4):221-9.

  15. Brahimi M, Saidi D, Touhami H, Bekadja MA. The use of CD45/SSC Dot Plots in the Classification of acute leukemias. J Hematol Thromb Dis. 2014;2(2):e107.

  16. Gupta A, Goyal M, Nidamanuri KR, Dattatreya PS. You dilemma, my identify: inusual immunogenetic profiles of pediatric B cell acute lymphoblastic leukemia. Indian J Pathol Microbiol. 2014;57(1):78-80.

  17. Aejaz S, Kumar S, Sabah I, Jan A. Prognostic significance of cell surface phenotype in acute lymphoblastic leukemia. South Asian J Cancer. 2015;4(2):91-4.

  18. Gredelj-Simec N, Jelić-Puskarić B, Ostojić A, Siftar Z, Fiala D, Kardum-Skelin I, et al. Diagnostic and prognostic significance of CD45 antigen expression in hematology malignancies with main focus on acute leukemia. Acta Med Croatica. 2011;65(1):45-52.

  19. Cario G, Rhein P, Mitlohner R, Zimmermann M, Bandapalli O, Romey R. Hight CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated to the ALL-BFM 2000 protocol. Haematologica. 2014;99(1):103-10.

  20. Bugarin C, Sarno J, Palmi C, Savino AM, Kronnie G, Dworzak M, et al. Fine Tuning of Surface CRLF2 Expression and Its Associated Signaling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. Haematologica. 2015;100(6):e229-32.

  21. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115(26):5393-7.

  22. Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, Tataglia M. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood. 2012;19(19):4476-9.

  23. Shochat C, Tal N, Bandapalli O, Palmi C, Ganmore I, Kronnie G. Gain-of-function mutations in interleukin-7 receptor (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208(5):901-8.




2020     |     www.medigraphic.com